

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2185)**

**VOLUNTARY ANNOUNCEMENT**  
**COMPLETION OF PATIENT ENROLLMENT FOR THE CLINICAL**  
**TRIAL OF BIOHEART® BIORESORBABLE SCAFFOLD (BRS)**  
**PRODUCT**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business advancement of the Group.

Reference is made to the Company’s prospectus published on December 13, 2021 (the “**Prospectus**”). Unless otherwise specified, capitalised terms used herein shall have the same meanings as defined in the Prospectus.

The board of directors of the Company (the “**Board**”) is pleased to announce that on February 16, 2022, the Company completed the patient enrollment process for the clinical trial of our bioresorbable scaffold (BRS) product, Bioheart®, a self-developed temporary scaffold that will be fully resorbed by the human body over time. It is a BRS system used in PCI procedures for the treatment of coronary artery disease. Bioheart® was recognized as an “innovative medical device” by the NMPA in February 2017 and is therefore eligible for an expedited approval process.

According to Frost & Sullivan, as of the date of this announcement, only two BRS products were commercialized in China, each of which was a first-generation BRS product with a strut thickness of over 150 µm. We are one of only four domestic players in China with second-generation BRS products at clinical trial stage. Since we completed the patient enrollment of the RCT earlier than the other competitors in China and no BRS product candidates in the global market had been reported to initiate an RCT as of the date of this announcement, Bioheart® is expected to be the world’s first second-generation BRS system approved for commercialization based on multi-center RCT Results.

Looking ahead, the Company will carry on its ongoing clinical programs and bring Bioheart® to the market. The Company will continue to strengthen its in-house research and development capabilities and bring innovation to clinical care.

**Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that Bioheart® will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People's Republic of China, February 16, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.*